Incyte Corporation

NASDAQ:INCY

Biotechnology

Healthcare
$117.80 -0.78%

-$0.77 today

Market cap
$24.01B
Beta
0.79
P/E (TTM)
13.7
EPS (TTM)
$7.18
52W Low $66.74High $112.29

Volume 1.21M

Average 1.58M

INCY Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Incyte CorporationNASDAQ: INCY

Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026

Net change in cash growth accelerates

Q2 FY2026 net change in cash of $521.26M rose 3834.9% year over year, ahead of the +109.5% change in trailing-twelve-month net change in cash. Sequentially, it rose 43.5% from the prior quarter. Over 3 fiscal years it compounded at +16.4% a year.

Context

  • Net change in cash amounted to 27.4% of revenue in FY2025, down 8.5 pp from a year earlier.
  • Net change in cash increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +3834.9% holds above the trailing-twelve-month pace of +109.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$521.26M+43.5% QoQ
Last fiscal yearDec 2025
$1.41B+192.4% YoY
LTMJun 2026
$2.03B+109.5% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3834.9%——
1 year+192.4%——
3-year CAGR+16.4%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
1.41B USD
Year-over-year change
+192.4%
4-year CAGR
+26.9%

Net Change in Cash vs competitors

How INCY compares with its peers on the latest reported figures

  • INCY's LTM Jun 2026 net change in cash of $2.03B is the largest of the 11 companies compared; the peer median is $103.7M.
  • Its year-over-year change of +109.5% is the 6th highest of 10, against a peer median of +200.8%.
  • Net change in cash amounts to 34.8% of revenue for INCY, versus a peer median of 13.4%.
INCY Competitors Peer median
Net Change in Cash for INCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$2.03B +109.5%+16.4%34.8%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 2026$939.03M +1795.9%+59.1%323.2%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$908.3M -1139.2%+42.1%5.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$641.62M +3223.9%—91.4%
GMABGenmab A/SLTM Jun 2026$207.09M —-28.3%5.0%
LEGNLegend Biotech CorporationLTM Sep 2026$181.76M +200.8%+85.0%13.4%
EXELExelixis, Inc.LTM Jul 2026$117.02M +443.9%—4.8%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$90.39M +288.1%——
VSTMVerastem, Inc.LTM Mar 2026$47.98M +36.3%+28.9%96.8%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$12.24M +104.6%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$1.57M -164.9%-61.9%—
Peer median (excluding INCY) $103.7M+200.8%+35.5%13.4%

Competitors are the stored peer set for INCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income948.58M340.66M597.6M32.62M1.29B
Depreciation & Amortization57.84M67.86M82.66M89.25M93.29M
Deferred Income Tax(465.6M)57.09M(158.9M)(85.55M)247.69M
Stock-Based Compensation183.01M188.42M215.89M266.06M249.35M
Change in Working Capital(14.57M)198.81M(248.65M)138.24M(527.16M)
Accounts Receivables(134.31M)(28.58M)(98.68M)(111.59M)(170.77M)
Inventory(20.97M)(67.5M)(170.15M)(127.63M)(58.51M)
Accounts Payables73.34M105.44M(167.95M)88.16M6.56M
Other Working Capital67.36M189.46M188.12M289.3M(304.44M)
Other Non-Cash Items40.23M117.11M7.89M(105.28M)63.69M
Operating Cash Flow749.49M969.94M496.49M335.34M1.41B
Capital Expenditures(181.01M)(77.83M)(32.49M)(86.26M)(58.87M)
Acquisitions (Net)00000
Purchases of Investments(268.68M)(79.86M)(466.02M)(258.37M)(303.38M)
Sales of Investments241.98M79.15M305.83M516.05M284.64M
Other Investing Activities00000
Investing Cash Flow(207.7M)(78.54M)(207.68M)157.52M(102.61M)
Debt Repayment(2.42M)(2.86M)(3.36M)(3.8M)(4.54M)
Common Stock Issued58.63M61.12M35.84M49.3M221.76M
Common Stock Repurchased000(2B)(19.1M)
Dividends Paid00000
Other Financing Activities(50.03M)(59.05M)(52.51M)(62.26M)(97.08M)
Financing Cash Flow6.18M(794K)(20.03M)(2.02B)101.04M
Effect of Forex Changes(3.53M)3.38M(6.82M)3.15M(1.94M)
Net Change in Cash544.43M893.98M261.95M(1.53B)1.41B
Free Cash Flow568.48M892.11M464M249.07M1.35B

Incyte Corporation

NASDAQ:INCY

Intrinsic Alpha fair value

Locked

Current Price

$117.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.